Patents by Inventor Sven-Erik Strand
Sven-Erik Strand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220242969Abstract: The present invention provides antibody polypeptides with binding specificity for prostate specific antigen (PSA), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies.Type: ApplicationFiled: April 11, 2022Publication date: August 4, 2022Inventors: Amanda Thuy Tran, Anders Axelsson, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Sven-Erik Strand, Urpo Juhani Lamminmäki
-
Patent number: 11332543Abstract: The present invention provides antibody polypeptides with binding specificity for prostate specific antigen (PSA), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies. The invention further provides use of said antibody polypeptides in the diagnosis and treatment of prostate cancer.Type: GrantFiled: October 4, 2016Date of Patent: May 17, 2022Assignee: FREDAX ABInventors: Amanda Thuy Tran, Anders Axelsson, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Sven-Erik Strand, Urpo Juhani Lamminmäki
-
Publication number: 20220125961Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.Type: ApplicationFiled: January 7, 2022Publication date: April 28, 2022Inventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
-
Publication number: 20220064333Abstract: The present invention provides antibody polypeptides with binding specificity for human kallikrein-2 (hK2), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies.Type: ApplicationFiled: September 16, 2021Publication date: March 3, 2022Inventors: Par Oskar Vilhelmsson Timmermand, Amanda Thuy Tran, Sven-Erik Strand, Urpo Juhani Lamminmaki, Kjell Sjostrom
-
Patent number: 11230609Abstract: The present invention provides antibody polypeptides with binding specificity for human kallikrein-2 (hK2), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies. The invention further provides use of said antibody polypeptides in the diagnosis and treatment of prostate cancer.Type: GrantFiled: August 30, 2018Date of Patent: January 25, 2022Assignee: Janssen Biotech, Inc.Inventors: Par Oskar Vilhelmsson Timmermand, Amanda Thuy Tran, Sven-Erik Strand, Urpo Juhani Lamminmaki, Kjell Sjostrom
-
Patent number: 10960048Abstract: This invention relates to ?1-microglobulin (A1M) for use in the diagnosis or treatment of malignancies requiring radionuclide diagnostics (RD), radionuclide therapy (RNT) or radioimmunotherapy (RIT), respectively, wherein A1M is used as a co-treatment to RD, RNT or RIT.Type: GrantFiled: February 25, 2016Date of Patent: March 30, 2021Assignee: Guard Therapeutics International ABInventors: Bo Åkerström, Sven-Erik Strand, Magnus Göran Gram, Amanda Thuy Tran
-
Publication number: 20200138986Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.Type: ApplicationFiled: November 11, 2019Publication date: May 7, 2020Inventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
-
Publication number: 20190169312Abstract: The present invention provides antibody polypeptides with binding specificity for human kallikrein-2 (hK2), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies.Type: ApplicationFiled: August 30, 2018Publication date: June 6, 2019Inventors: Par Oskar Vilhelmsson Timmermand, Amanda Thuy Tran, Sven-Erik Strand, Urpo Juhani Lamminmaki, Kjell Sjostrom
-
Patent number: 10100125Abstract: The present invention provides antibody polypeptides with binding specificity for human kallikrein-2 (hK2), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2 and SEQ ID NO: 3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO: 4 and SEQ ID NO: 5 and SEQ ID NO: 6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies. The invention further provides use of said antibody polypeptides in the diagnosis and treatment of prostate cancer.Type: GrantFiled: November 19, 2014Date of Patent: October 16, 2018Assignee: Diaprost ABInventors: Par Oskar Vilhelmsson Timmermand, Amanda Thuy Tran, Sven-Erik Strand, Urpo Juhani Lamminmaki, Kjell Sjostrom
-
Publication number: 20180273634Abstract: The present invention provides antibody polypeptides with binding specificity for prostate specific antigen (PSA), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies.Type: ApplicationFiled: October 4, 2016Publication date: September 27, 2018Inventors: Amanda Thuy Tran, Anders Axelsson, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Sven-Erik Strand, Urpo Juhani Lamminmäki
-
Publication number: 20180243369Abstract: This invention relates to ?1-microglobulin (A1M) for use in the diagnosis or treatment of malignancies requiring radionuclide diagnostics (RD), radionuclide therapy (RNT) or radioimmunotherapy (RIT), respectively, wherein A1M is used as a co-treatment to RD, RNT or RIT.Type: ApplicationFiled: February 25, 2016Publication date: August 30, 2018Applicant: A1M PHARMA ABInventors: Bo Akerstrom, Sven-Erik STRAND, Magnus Göran GRAM, Amanda Thuy TRAN
-
Publication number: 20160369009Abstract: The present invention provides antibody polypeptides with binding specificity for human kallikrein-2 (hK2), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2 and SEQ ID NO: 3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO: 4 and SEQ ID NO: 5 and SEQ ID NO: 6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies. The invention further provides use of said antibody polypeptides in the diagnosis and treatment of prostate cancer.Type: ApplicationFiled: November 19, 2014Publication date: December 22, 2016Applicant: FREDAX ABInventors: Par Oskar Vilhelmsson Timmermand, Amanda Thuy Tran, Sven-Erik Strand, Urpo Juhani Lamminmaki
-
Publication number: 20160317683Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.Type: ApplicationFiled: April 21, 2016Publication date: November 3, 2016Inventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
-
Patent number: 9345782Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.Type: GrantFiled: October 26, 2012Date of Patent: May 24, 2016Assignee: FREDAX ABInventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
-
Publication number: 20140286862Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.Type: ApplicationFiled: October 26, 2012Publication date: September 25, 2014Inventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
-
Patent number: 6251394Abstract: A method and a system is described for reducing non-target levels of specific molecules intended for diagnostic and/or therapeutic applications to vertebrate hosts, wherein said molecules are administered to a vertebrate host and kept therein for a certain time in order to be concentrate to the target by being attached thereto. The molecules which are not attached to the target are removed from the blood circulation system or at least reduced to a lower concentration by passing the blood through an extra-corporeal device.Type: GrantFiled: October 12, 1993Date of Patent: June 26, 2001Assignee: Mitra Medical Technology ABInventors: Rune Nilsson, Lars Lindgren, Kristina Norrgren, Bengt Sandberg, Hans Olof Sjögren, Sven-Erik Strand